Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

7.5%

4 terminated/withdrawn out of 53 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

55%

11 of 20 completed trials have results

Key Signals

15 recruiting11 with results

Enrollment Performance

Analytics

Phase 2
17(36.2%)
N/A
17(36.2%)
Phase 1
12(25.5%)
Early Phase 1
1(2.1%)
47Total
Phase 2(17)
N/A(17)
Phase 1(12)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (53)

Showing 20 of 53 trials
NCT05918263Not ApplicableActive Not Recruiting

Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial

Role: collaborator

NCT07050433Recruiting

COMPASS Study for Metastatic Castration-resistant Prostate Cancer

Role: collaborator

NCT06305598Phase 1Recruiting

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Role: collaborator

NCT05766371Phase 2Recruiting

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Role: collaborator

NCT06171139Not ApplicableRecruiting

Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer

Role: collaborator

NCT05113537Phase 1Recruiting

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Role: collaborator

NCT05435495Recruiting

Mechanisms of Resistance to PSMA Radioligand Therapy

Role: collaborator

NCT06040125Not ApplicableRecruiting

Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial

Role: collaborator

NCT06616597Phase 2Recruiting

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Role: collaborator

NCT05320406Phase 2Active Not Recruiting

RElugolix VErsus LeUprolide Cardiac Trial

Role: collaborator

NCT05471414Not ApplicableActive Not Recruiting

Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer

Role: collaborator

NCT05327465Not ApplicableRecruiting

Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy

Role: collaborator

NCT06059118Phase 2Recruiting

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Role: collaborator

NCT03492424Recruiting

Ablative Therapy in the Management of Prostate Cancer

Role: collaborator

NCT06046040Phase 1Recruiting

TmPSMA-02 in mCRPC

Role: collaborator

NCT03007732Phase 2Completed

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Role: collaborator

NCT04090528Phase 2Active Not Recruiting

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Role: collaborator

NCT04447703Not ApplicableCompleted

Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study

Role: collaborator

NCT06126731Phase 1Recruiting

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Role: collaborator

NCT02735252Not ApplicableActive Not Recruiting

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

Role: collaborator